Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have discovered heterocyclic carbonyl derivatives acting as muscarinic M4 receptor agonists potentially useful for the treatment of pain, substance abuse and dependency, schizophrenia, Alzheimer’s disease and sleep disorders.